The Role of Genetics in Cognitive Remediation in Schizophrenia: A Systematic Review

Overview

Journal Schizophr Res Cogn

Specialty Psychology

Date 2019 Dec 14

PMID 31832337

Citations 6

Authors

Rafael Penades

Marta Bosia

Rosa Catalan

Marco Spangaro

Clemente Garcia-Rizo

Silvia Amoretti

Miquel Bioque

Miquel Bernardo

Affiliations

Soon will be listed here.

Abstract

The role of genetics in cognitive remediation therapies in schizophrenia has not been completely understood yet. Different genes involved in neurotrophic, dopaminergic and serotonin systems have reported to influence cognitive functioning in schizophrenia. These genetic factors could also be contributing to the variability in responsiveness to cognitive treatments. No comprehensive synthesis of the literature of the role of genetics in the context of cognitive remediation has been conducted until now. We aimed to systematically review the published works through three electronic database searches: PubMed, Scopus, and the Cochrane Library. Eligible studies revealed a rising interest in the field although the number of published studies was rather small (n = 10). Eventually, promising results showing a relationship between some phenotypic variations based on different polymorphisms and different levels of responsivity to cognitive remediation therapies have been described although results are still inconclusive. In case those findings will be replicated, they could be guiding future research and informing clinical decision-making in the next future.

Citing Articles

Through the lens of schizophrenia: Recognizing negative facial expressions and family patterns.

Shateri L, Yari Renani H, Rudsari A, Hashemi Nosratabad T, Saeidi Z Schizophr Res Cogn. 2024; 39:100336.

PMID: 39559797 PMC: 11570855. DOI: 10.1016/j.scog.2024.100336.

Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations.

Vita A, Barlati S, Cavallaro R, Mucci A, Riva M, Rocca P Front Psychiatry. 2024; 15:1451832.

PMID: 39371908 PMC: 11450451. DOI: 10.3389/fpsyt.2024.1451832.

SLC39A8.p.(Ala391Thr) is associated with poorer cognitive ability: a cross-sectional study of schizophrenia and the general UK population.

Smart S, Legge S, Fenner E, Pardinas A, Woolway G, Lynham A medRxiv. 2024; .

PMID: 39371177 PMC: 11451698. DOI: 10.1101/2024.09.18.24313865.

Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art.

Harvey P, Bosia M, Cavallaro R, Howes O, Kahn R, Leucht S Schizophr Res Cogn. 2022; 29:100249.

PMID: 35345598 PMC: 8956816. DOI: 10.1016/j.scog.2022.100249.

Integrated Omic Analyses Identify Pathways and Transcriptomic Regulators Associated With Chemical Alterations of In Vitro Neural Network Formation.

Marable C, Frank C, Seim R, Hester S, Henderson W, Chorley B Toxicol Sci. 2021; 186(1):118-133.

PMID: 34927697 PMC: 11460064. DOI: 10.1093/toxsci/kfab151.

References

Keefe R, Bilder R, Harvey P, Davis S, Palmer B, Gold J . Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006; 31(9):2033-46. DOI: 10.1038/sj.npp.1301072. View

Lindenmayer J, Khan A, Lachman H, McGurk S, Goldring A, Thanju A . COMT genotype and response to cognitive remediation in schizophrenia. Schizophr Res. 2015; 168(1-2):279-84. PMC: 4591188. DOI: 10.1016/j.schres.2015.07.037. View

Kim K, Lee S, Kegelman T, Su Z, Das S, Dash R . Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol. 2011; 226(10):2484-93. PMC: 3130100. DOI: 10.1002/jcp.22609. View

Grynszpan O, Perbal S, Pelissolo A, Fossati P, Jouvent R, Dubal S . Efficacy and specificity of computer-assisted cognitive remediation in schizophrenia: a meta-analytical study. Psychol Med. 2010; 41(1):163-73. DOI: 10.1017/S0033291710000607. View

Medalia A, Richardson R . What predicts a good response to cognitive remediation interventions?. Schizophr Bull. 2005; 31(4):942-53. DOI: 10.1093/schbul/sbi045. View

Bosia M, Zanoletti A, Spangaro M, Buonocore M, Bechi M, Cocchi F . Factors affecting cognitive remediation response in schizophrenia: the role of COMT gene and antipsychotic treatment. Psychiatry Res. 2014; 217(1-2):9-14. DOI: 10.1016/j.psychres.2014.02.015. View

Thomas E, Bozaoglu K, Rossell S, Gurvich C . The influence of the glutamatergic system on cognition in schizophrenia: A systematic review. Neurosci Biobehav Rev. 2017; 77:369-387. DOI: 10.1016/j.neubiorev.2017.04.005. View

Wilkening S, Chen B, Lorenzo Bermejo J, Canzian F . Is there still a need for candidate gene approaches in the era of genome-wide association studies?. Genomics. 2009; 93(5):415-9. DOI: 10.1016/j.ygeno.2008.12.011. View

Harvey P, Aslan M, Du M, Zhao H, Siever L, Pulver A . Factor structure of cognition and functional capacity in two studies of schizophrenia and bipolar disorder: Implications for genomic studies. Neuropsychology. 2015; 30(1):28-39. PMC: 4693294. DOI: 10.1037/neu0000245. View

10.

Hong C, Liou Y, Tsai S . Effects of BDNF polymorphisms on brain function and behavior in health and disease. Brain Res Bull. 2011; 86(5-6):287-97. DOI: 10.1016/j.brainresbull.2011.08.019. View

11.

Davies G, Lam M, Harris S, Trampush J, Luciano M, Hill W . Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat Commun. 2018; 9(1):2098. PMC: 5974083. DOI: 10.1038/s41467-018-04362-x. View

12.

Ira E, Zanoni M, Ruggeri M, Dazzan P, Tosato S . COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation. J Psychiatry Neurosci. 2013; 38(6):366-80. PMC: 3819150. DOI: 10.1503/jpn.120178. View

13.

Bosia M, Bechi M, Pirovano A, Buonocore M, Lorenzi C, Cocchi F . COMT and 5-HT1A-receptor genotypes potentially affect executive functions improvement after cognitive remediation in schizophrenia. Health Psychol Behav Med. 2015; 2(1):509-516. PMC: 4346068. DOI: 10.1080/21642850.2014.905206. View

14.

Spangaro M, Bosia M, Zanoletti A, Bechi M, Cocchi F, Pirovano A . Cognitive dysfunction and glutamate reuptake: effect of EAAT2 polymorphism in schizophrenia. Neurosci Lett. 2012; 522(2):151-5. DOI: 10.1016/j.neulet.2012.06.030. View

15.

Smeland O, Frei O, Kauppi K, Hill W, Li W, Wang Y . Identification of Genetic Loci Jointly Influencing Schizophrenia Risk and the Cognitive Traits of Verbal-Numerical Reasoning, Reaction Time, and General Cognitive Function. JAMA Psychiatry. 2017; 74(10):1065-1075. PMC: 5710474. DOI: 10.1001/jamapsychiatry.2017.1986. View

16.

Mak M, Samochowiec J, Tybura P, Bienkowski P, Karakiewicz B, Zaremba Pechmann L . The efficacy of cognitive rehabilitation with RehaCom programme in schizophrenia patients. The role of selected genetic polymorphisms in successful cognitive rehabilitation. Ann Agric Environ Med. 2013; 20(1):77-81. View

17.

Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V . Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry. 2004; 161(10):1798-805. DOI: 10.1176/ajp.161.10.1798. View

18.

Fisher M, Mellon S, Wolkowitz O, Vinogradov S . Neuroscience-informed Auditory Training in Schizophrenia: A Final Report of the Effects on Cognition and Serum Brain-Derived Neurotrophic Factor. Schizophr Res Cogn. 2015; 3:1-7. PMC: 4685735. DOI: 10.1016/j.scog.2015.10.006. View

19.

Bryce S, Rossell S, Lee S, Lawrence R, Tan E, Carruthers S . Neurocognitive and Self-efficacy Benefits of Cognitive Remediation in Schizophrenia: A Randomized Controlled Trial. J Int Neuropsychol Soc. 2018; 24(6):549-562. DOI: 10.1017/S1355617717001369. View

20.

Panizzutti R, Hamilton S, Vinogradov S . Genetic correlate of cognitive training response in schizophrenia. Neuropharmacology. 2012; 64:264-7. PMC: 3448064. DOI: 10.1016/j.neuropharm.2012.07.048. View